1. Home
  2. ASGN vs AGIO Comparison

ASGN vs AGIO Comparison

Compare ASGN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ASGN Incorporated

ASGN

ASGN Incorporated

HOLD

Current Price

$51.74

Market Cap

2.1B

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.41

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASGN
AGIO
Founded
1985
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
1992
2013

Fundamental Metrics

Financial Performance
Metric
ASGN
AGIO
Price
$51.74
$27.41
Analyst Decision
Hold
Buy
Analyst Count
5
8
Target Price
$50.20
$36.25
AVG Volume (30 Days)
477.4K
943.3K
Earning Date
02-04-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.96
N/A
Revenue
$3,985,300,000.00
$44,791,000.00
Revenue This Year
N/A
$27.83
Revenue Next Year
$0.57
$133.46
P/E Ratio
$17.63
N/A
Revenue Growth
N/A
36.26
52 Week Low
$39.25
$22.24
52 Week High
$93.95
$46.00

Technical Indicators

Market Signals
Indicator
ASGN
AGIO
Relative Strength Index (RSI) 60.16 45.61
Support Level $48.26 $26.25
Resistance Level $51.81 $29.93
Average True Range (ATR) 1.74 1.13
MACD -0.04 0.09
Stochastic Oscillator 83.33 31.79

Price Performance

Historical Comparison
ASGN
AGIO

About ASGN ASGN Incorporated

ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: